SLC5A2 and metabolic syndrome: Similar findings were observed with empagliflozin, where it was noted that SGLT2 inhibition may attenuate platelet reactivity through multiple pathways, including improved glycemic control, reduction of dyslipidemia and reduced oxidative stress [11].